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I. Introduction 
Oxytocin and vasopressin containing [14C]glycine 
in the C-terminus [1 ] have significantly aided research 
on new metabolic pathways of these hormones. Such 
studies demonstrated the presence in various tissues of 
enzymes which catalyze the hydrolysis of peptide bonds 
located in acyclic portion of the hormones [2,3] and 
have led to additional investigations of these kinds of 
enzymatic activities in other biological systems [4-9].  
Enzymes which release glycinamide or the C-terminal 
dipeptides of oxytocin and vasopressin have now 
been partially purified [10,11 ]. Additional enzymatic 
mechanisms capable of neurohypophyseal hormone 
inactivation are known, including disulfide reductase 
in liver [12] as well as enzymes which can degrade 
the hormones from the N-terminus [13-15]. 
In order to investigate in greater detail the 
mechanisms ofneurohypophyseal hormone inactiva- 
tion from the N-terminus, we have synthesized and 
Nomenclature is in accordance with IUPAC-IUB Rules on 
Biochemical Nomenclature, Biochem. J. 126, 773 (1972); 
and J. Biol. Chem. 242, 555 (1967). All optically active 
amino acids are of the L configuration. Other abbreviations: 
ONp, nitrophenyl ester; HOAc, acetic acid; DMF, 
N,N'-dimethylformamide; DCC1, dicyclohexylcarbodiimide; 
t.l.c., thin layer chromatography. All t.l.c, were run on 
silica gel plates from Quantum Industries; unlabeled 
compounds were visualized by the method of H. Zahn and 
E. Rexroth (1955) Z. Analyt. Chem. 148, 181-186. On 
high voltage lectrophoresis, unlabeled compot/nd was 
detected with ninhydrin. The biological ctivity of the 
hormone was measured against the U.S.P. Posterior Pituitary 
Reference Standard; the four-point design was used for the 
assay. 
report here oxytocin labeled with [14C] tyrosine. 
[2-14C(U)Tyrosine]oxytocin was synthesized by the 
general solid-phase procedure [16]. 
2. Results and discussion 
Boc-glycine was esterified to chloromethylated 
copolystyrene-2% divinylbenzene [17] (1.06 mmol 
C1/g) at a substitution of 0.36 mmol/g resin as 
determined by hydrolysis in 6 N HCl/propionic acid 
(1:1) [18] followed by amino acid analysis [19] 
(Beckman 120C amino acid analyzer). An individual 
cycle for incorporation of each additional amino 
acid involved washing with HOAc followed by 
CH2C12, removal of the N-protecting group with 
25% TFA in CH2C12, followed by neutralization with 
10% diisopropylethylamine, andthen washing with 
CH2C12 and acylation with the appropriate 
N-protected amino acid. The final washes consisted 
of DMF/CH2C12, 1:1, v/v and CHC13/MeOH, 2:1, v/v. 
Boc-Leu, Boc-Pro, Boc-Cys(Bzl), Boc-Ile and 
Boc-14C(U)Tyr were added in two-fold molar excess 
along with a two-fold molar excess of DCCI and the 
reaction was carried out in CH2C12 for 2 h. Extent of 
acylation was monitored by the ninhydrin reaction 
[20] and in most cases a repeat of the coupling reac- 
tion (in DMF/CH2C12, 1:1, v/v) was required. Boc-Gln, 
Bee-Ash, and the N-terminal Z-Cys(Bzl) were 
incorporated astheir nitrophenyl esters (5 meq) in 
the presence of 1,2,4 triazole (1.3 meq) [21] in DMF 
during an overnight reaction. For incorporation of
14C(U)tyrosine, 30 mCi of uniformly labeled [14C] 
tyrosine (486 Ci/mol, ~ 0.06 mmol; Amersham- 
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Seafle) was examined by t.l.c. (95% EtOH/H~O, 7.3, 
v/v; PrOH/H20 7:3, v/v) and found to be 98% radio- 
chemically pure. The labeled amino acid was diluted 
to a specific radioactivity of 93.7 Ci/mol (0.32 mmol) 
by addition of unlabeled tyrosine, and was treated 
with Boc-azide according to the method of Schnabel 
[22]. The reaction was followed by t.l.c. (CHC13/ 
MeOH/HOAc, 85:10:5, v/v/v; $1) and after 3 days 
the reaction mixture was extracted with Et20, the" 
aqueous phase acidified with citric acid, and again 
extracted with ethyl acetate and ether. This organic 
layer was dried to an oil which revealed two radio- 
active spots on t.l.c. (S~), corresponding toBoc- 
tyrosine and di-Boc-tyrosine. Based on radioactivity, 
the yield of this reaction was 85%. The oil was added 
to 0.45 g of free heptapeptide-resin (0.16 mmol 
heptapeptide). The resultant octapeptide was elongated 
to the nonapeptide as described, the protected nona- 
peptide was cleaved from the resin by ammonolysis, 
precipitated from DFM/H20, and repeatedly washed 
with water by centrifugation. This material contained 
two radioactive components upon t.l.c. (S] and 
CHCla/MeOH, 8:2). The nonapeptide was deprotected 
with Na in liquid ammonia [23], oxidized to the 
disulfide with ferricyanide [24], and subjected to 
partition chromatography [25] on a column of 
Sephadex G-25 (200-400 mesh, 108 X 0.9 cm) 
which had been equilibrated with the lower phase 
of the solvent system 1-BuOH/benzene/pyridine/ 
HOAc/H20 (600:200:100:1:900). Thehormone 
was eluted with the upper phase of the solvent system 
and detected by scintillation counting (Beckman 
LS-355 Liquid Scintillation Spectrometer; scintilla- 
tion cocktail 3A70 from Research Products Intl.) 
at an Rf value of 0.22 (Rf of 0.24 reported for 
oxytocin [25] ). 
Fractions containing the radioactive peak were 
pooled, the organic phase was removed under educed 
pressure, and the aqueous phase was adjusted to 0.2% 
acetic acid. An aliquot of this material was examined 
by t.l.c, in two solvent systems and by high voltage 
paper electrophoresis (see fig. 1). The material exhibited 
an avian vasodepressor activity [26,27] of 463 -+ 11 
U/mg*, a value comparable to that reported for 
*Concentration of the hormone was determined on the basis 
of specific radioactivity of the hormone and cpm/ml of 
solution. 
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Fig. 1. Thin-layer chromatography and high voltage lectro- 
phoresis of [2-s4C(U)Tyr] oxytocin. In each case, 125 000 
cpm of radioactivity (spec. act. of compound, 93.7 Ci/mol) 
was applied. Peaks were detected using a Packard Model 
7201 chromatogram scanner; unlabeled oxytocin was used as 
standard. ( 4.) Thinqayer chromatography on silica gel in the 
solvent system 1-BuOH/HOAc/H~O, 4:1:1, v/v/v. (B) Thin- 
layer chromatography in the solvent system 1-BuOH/ 
pyridine/H20, 20:10:11, v/v/v. (C) High voltage lectro- 
phoresis in 10% pyridine acetate buffer, pH 3.5. Electro- 
phoresis was carried out at 3000 V for 1 h. O -- origin, with 
distances given in cm. F = solvent front. 
purified oxytocin [28,29]. After bioassay, 0.5 ml 
aliquots of the hormone solution, at a concentration 
of 0.1 mg/ml (2.06 × 107 dpm/ml) in 0.2% acetic 
acid, were sealed in ampules which were sterilized in a 
steam bath for 10 min and stored at 4°C. 
The specific radioactivity of this hormone is
93.7 Ci/mol, which is significantly higher than that 
previously reported for 14C-labeled neurohypophyseal 
hormones [1 ], and should overcome some of the 
problems encountered in the past in using 14C-labeled 
neurohypophyseal hormones for in vivo studies. 
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